Viridian Therapeutics Launches FDA-Approved Drug for Thyroid Eye Disease
Viridian Therapeutics (VRDN) launched its first commercial product, Lumvoa, following U.S. FDA approval as a treatment for thyroid eye disease, a rare autoimmune condition affecting the eyes.
Tickers: $VRDN